NervGen Pharma (TSE:NGEN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NervGen Pharma’s Chief Medical Officer will present a clinical trial update for NVG-291, a therapeutic peptide designed to repair nervous system damage, at the International Spinal Cord Society Annual Meeting. The presentation will discuss the trial’s design and early results, which aim to demonstrate NVG-291’s potential in promoting neural repair in spinal cord injuries (SCI).
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
